Sign up
Pharma Capital

Shares of Neovasc advance after company raises US$7.1mln through warrants to boost cash flow

Receipts will provide funding for additional four months
Researcher looking through miscroscope
The stock rose 11% on the news

Shares of Neovasc Inc. (NASDAQ:NVCN) gained after the biotechnology company said it raised US$7.1mln, enough to fund the company for four months, after investors exercised warrants offered by the firm.

The stock of the firm, which is focused on treating infectious diseases, rose 11% to US$0.06 at 11:36 a.m.

Investors took up 4.9mln warrants, the company said in a statement. Each Series C warrant entitles the holder to receive one Series C unit that is made up of one share of common stock, one Series A warrant and one Series B warrant, it said.

“The receipt into Treasury is significant,” Neovasc said. “We believe it is sufficient to substantially fund the company for an additional fourth months at our current burn rate” and increase “our current cash on hand by almost 60%.”

Register here to be notified of future NVC Company articles
View full NVC profile View Profile
View All

Related Articles

cancer scan
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.